May. 7 at 8:45 PM
RSV war shifting from science to distribution.
$MRNA is lagging as
$PFE /
$GSK continue locking supply contracts and hospital access.
👉Click to view @NasdaqPulse for timely updates amid the volatility.
Key checks:
• durability gap vs subunit vaccines
• CDC narrows RSV eligibility → smaller market
• incumbents dominate procurement channels
mRESVIA is now an access story, not a breakthrough narrative.
Ayers’ view: Moderna lost ground on rollout + relationships, not just efficacy.
In 2026, RSV upside still priced more into
$PFE/
$GSK while
$MRNA trades as a re-rating story.